Form 8-K - Current report:
SEC Accession No. 0001213900-22-041295
Filing Date
2022-07-25
Accepted
2022-07-25 16:00:30
Documents
13
Period of Report
2022-07-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea163216-8k_inmunebio.htm   iXBRL 8-K 25540
2 PRESS RELEASE, DATED JULY 25, 2022 ea163216ex99-1_inmunebio.htm EX-99.1 11391
  Complete submission text file 0001213900-22-041295.txt   215063

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20220725.xsd EX-101.SCH 2962
4 XBRL LABEL FILE inmb-20220725_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20220725_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea163216-8k_inmunebio_htm.xml XML 3709
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 221103310
SIC: 2836 Biological Products, (No Diagnostic Substances)